Kan Yonemori

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Toshihiko Doi, Kohei Shitara, Yoichi Naito et al. · The Lancet Oncology · 2017 · 474 citations

Breast Oncology, Oncology, Medicine +10

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

Éric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 374 citations

Chemotherapy Versus Chemotherapy, Oncology, Platinum-refractory Ovarian Cancer +9

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo et al. · Cancer Science · 2019 · 351 citations · Full text

Actionable Gene Aberrations, Cancer Pathology, Hospital‐based Study +22

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

Makiko Ono, Hitoshi Tsuda, Chikako Shimizu et al. · Breast Cancer Research and Treatment · 2011 · 300 citations

Breast Oncology, Cancer Immunosurveillance, Medicine +9

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

Aditya Bardia, Xichun Hu, Rebecca Dent et al. · New England Journal of Medicine · 2024 · 297 citations